Uncertainties in Screening and Prevention of Group B Streptococcus Disease

Kirsty Le Doare, Paul T Heath, Jane Plumb, Natalie A Owen, Peter Brocklehurst, Lucy C Chappell, Kirsty Le Doare, Paul T Heath, Jane Plumb, Natalie A Owen, Peter Brocklehurst, Lucy C Chappell

Abstract

In autumn 2016, the UK Department of Health (now Department of Health and Social Care) convened 2 meetings to discuss how to address research evidence gaps in order to minimize the impact of infant group B streptococcus (GBS) disease in the United Kingdom. At that meeting, a number of research priorities were highlighted, including improving the screening for GBS colonization in pregnant women, offering intrapartum antibiotic prophylaxis and point-of-care testing, and understanding the effect of widespread intrapartum antibiotic use on long-term infant health. Further discussions involved investigating the feasibility of a large prospective study of pregnant women and their infants in order to understand the role of antibodies in the protection against GBS disease in infancy following maternal exposure to GBS colonization. Here, we summarize the research uncertainties identified at that meeting.

Keywords: group B streptococcus; maternal; neonatal; screening; vaccine.

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

References

    1. Russell NJ, Seale AC, O’Driscoll M, et al. ; GBS Maternal Colonization Investigator Group Maternal colonization with group B streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis 2017; 65:100–11.
    1. Seale AC, Bianchi-Jassir F, Russell NJ, et al. . Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis 2017; 65:200–19.
    1. Kohli-Lynch M, Russell NJ, Seale AC, et al. . Neurodevelopmental impairment in children after group B streptococcal disease worldwide: systematic review and meta-analyses. Clin Infect Dis 2017; 65:190–9.
    1. O’Sullivan CP, Lamagni T, Patel D, et al. Group B streptococcal disease in UK and Irish infants younger than 90 days, 2014-15: a prospective surveillance study. Lancet Infect Dis. 2019;19(1):83-90. Epub 2018 Nov 26. doi:10.1016/S1473-3099(18)30555-3.
    1. Muller-Pebody B, Johnson AP, Heath PT, et al. . Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed 2011; 96:F4–8.
    1. Le Doare K, O’Driscoll M, Turner K, et al. ; GBS Intrapartum Antibiotic Investigator Group Intrapartum antibiotic chemoprophylaxis policies for the prevention of group B streptococcal disease worldwide: systematic review. Clin Infect Dis 2017; 65:143–51.
    1. Royal College of Obstetrics and Gynaecology. Prevention of early‐onset neonatal group B streptococcal disease. London: Royal College of Obstetrics and Gynaecology, 2017.
    1. National Institute for Health and Care Excellence. Neonatal infection (early onset): antibiotics for prevention and treatment. London: National Institute for Health and Care Excellence, 2012.
    1. Heath PT. Group B streptococcus. London: Royal College of Paediatrics and Child Health, 2016.
    1. Seedat F, Stinton C, Patterson J, et al. . Adverse events in women and children who have received intrapartum antibiotic prophylaxis treatment: a systematic review. BMC Pregnancy Childbirth 2017; 17:247.
    1. ACOG Committee Opinion. Prevention of early-onset group B streptococcal disease in newborns. Number 173–June 1996. Committee on Obstetric Practice. American College of Obstetrics and Gynecologists. Int J Gynaecol Obstet 1996; 54:197–205.
    1. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51:1–22.
    1. Colbourn T, Gilbert R. An overview of the natural history of early onset group B streptococcal disease in the UK. Early Hum Dev 2007; 83:149–56.
    1. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1–36.
    1. Centers for Diseases Control and Prevention. Active bacterial core surveillance (ABCs) report. Emerging infections program network group B streptococcus, 2015. CDC: Atlanta, GA; 2015.
    1. Obstetric, Gynecology and Paediatric Medicine Society. Preventie van neonatale groep B streptokokken. Amsterdam, 2008.
    1. National Screening Committee. The UK NSC recommendation on Group B streptococcus screening in pregnancy. 2017.
    1. Daniels JP, Gray J, Pattison HM, Gray R, Hills RK, Khan KS; GBS Collaborative Group Intrapartum tests for group B streptococcus: accuracy and acceptability of screening. BJOG 2011; 118:257–65.
    1. Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal group B streptococcal colonization. Cochrane Database Syst Rev 2014; CD007467.
    1. Di Renzo GC, Melin P, Berardi A, et al. . Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference. J Matern Fetal Neonatal Med 2015; 28:766–82.
    1. Seedat F, T-PS. Universal antenatal culture-based screening for maternal group B streptococcus (GBS) carriage to prevent early-onset GBS disease. External review against programme appraisal criteria for the UK National Screening - Phililps, S Committee. Warwick Medical School, Warwick, UK 2016.
    1. Ledger WJ, Blaser MJ. Are we using too many antibiotics during pregnancy? BJOG 2013; 120:1450–2.
    1. Reed BD, Schibler KR, Deshmukh H, Ambalavanan N, Morrow AL. The impact of maternal antibiotics on neonatal disease. J Pediatr 2018; 197:97–103.e3.
    1. Mueller NT, Bakacs E, Combellick J, Grigoryan Z, Dominguez-Bello MG. The infant microbiome development: mom matters. Trends Mol Med 2015; 21:109–17.
    1. Azad MB, Konya T, Persaud RR, et al. ; CHILD Study Investigators Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG 2016; 123:983–93.
    1. Stearns JC, Simioni J, Gunn E, et al. . Intrapartum antibiotics for GBS prophylaxis alter colonization patterns in the early infant gut microbiome of low risk infants. Sci Rep 2017; 7:16527.
    1. Corvaglia L, Tonti G, Martini S, et al. . Influence of intrapartum antibiotic prophylaxis for group B streptococcus on gut microbiota in the first month of life. J Pediatr Gastroenterol Nutr 2016; 62:304–8.
    1. Almeida A, Rosinski-Chupin I, Plainvert C, et al. . Parallel evolution of group B streptococcus hypervirulent clonal complex 17 unveils new pathoadaptive mutations. mSystems 2017; 2 pii:e00074-17.
    1. Pietrocola G, Arciola CR, Rindi S, Montanaro L, Speziale P. Streptococcus agalactiae non-pilus, cell wall-anchored proteins: involvement in colonization and pathogenesis and potential as vaccine candidates. Front Immunol 2018; 9:602.
    1. Seedat F, Brown CS, Stinton C, et al. . Bacterial load and molecular markers associated with early-onset group B streptococcus: a systematic review and meta-analysis. Pediatr Infect Dis J 2018; 37:e306–14.
    1. Gladstone RA, Jefferies JM, Tocheva AS, et al. . Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Vaccine 2015; 33:2015–21.
    1. Jauneikaite E, Kapatai G, Davies F, et al. . Serial clustering of late-onset group B streptococcal infections in the neonatal unit: a genomic re-evaluation of causality. Clin Infect Dis 2018; 67:854–60.
    1. McKenna JP, Cox C, Fairley DJ, et al. . Loop-mediated isothermal amplification assay for rapid detection of Streptococcus agalactiae (group B streptococcus) in vaginal swabs—a proof of concept study. J Med Microbiol 2017; 66:294–300.
    1. National Institute for Healthcare Research Health Technology Assessment HTA - 13/82/04 Accuracy of a rapid intrapartum test for maternal group B streptococcal colonisation and its potential to reduce antibiotic usage in mothers with risk factors (GBS2). This is a grant not a publication and is found listed on the NIHR HTA website 2013.
    1. Kapatai G, Patel D, Efstratiou A, Chalker VJ. Comparison of molecular serotyping approaches of Streptococcus agalactiae from genomic sequences. BMC Genomics 2017; 18:429.
    1. Zhou L, Yu SJ, Gao W, Yao KH, Shen AD, Yang YH. Serotype distribution and antibiotic resistance of 140 pneumococcal isolates from pediatric patients with upper respiratory infections in Beijing, 2010. Vaccine 2011; 29:7704–10.
    1. Kobayashi M, Vekemans J, Baker CJ, Ratner AJ, Le Doare K, Schrag SJ. Group B streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries. F1000Res 2016; 5:2355.
    1. Baker CJ, Carey VJ, Rench MA, et al. . Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis 2014; 209:781–8.
    1. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753–6.
    1. Lin FY, Weisman LE, Azimi PH, et al. . Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004; 190:928–34.
    1. Dangor Z, Kwatra G, Izu A, et al. . Correlates of protection of serotype-specific capsular antibody and invasive group B streptococcus disease in South African infants. Vaccine 2015; 33:6793–9.
    1. Lin FY, Philips JB 3rd, Azimi PH, et al. . Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 2001; 184:1022–8.
    1. Le Doare K, Heath PT, Mawas F, Madhi S, Kampmann B, Gorringe A.. Standardizing GBS capsular antibody concentration and functional assays to expedite GBS vaccine licensure (development). BMGF Grant number OPP1153630. Bill and Melinda Gates Foundation, Seattle, 2016.
    1. Pfizer awarded grant to evaluate vaccine to protect newborns against group B streptococcus infection. 2017. Available at: . Accessed 1 April 2018.
    1. MinervaX is pursuing the development of a novel vaccine candidate against group B streptococci (GBS). Minervax: 2016. Available at: . Accessed 3 January 2019.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj